Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results

被引：1

作者：

Liu, Joyce ^{[1
]}

O'Malley, David ^{[2
,3
]}

Van Nieuwenhuysen, Els ^{[4
]}

Moore, Kathleen ^{[5
]}

Hamilton, Erika ^{[6
]}

Yeku, Oladapo ^{[7
]}

Bouberhan, Sara ^{[7
]}

Hou, June ^{[8
]}

Schroeder, David ^{[9
]}

Wang, Bin ^{[10
]}

Yoo, Suk-Young ^{[10
]}

Govindraj, Shilpa ^{[11
]}

Brouwer-Visser, Jurriaan ^{[12
]}

Peterman, Mary ^{[13
]}

Schmidt, Tamara ^{[13
]}

Barnes, Brigid ^{[13
]}

Lowy, Israel ^{[13
]}

Uldrick, Thomas ^{[13
]}

Miller, Elizabeth ^{[13
]}

O'Cearbhaill, Roisin ^{[14
,15
]}

机构：

[1] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] James Canc Ctr, Div Gynecol Oncol Obstet & Gynecol, Columbus, OH USA

[4] Leuven Canc Inst, Gynaecol & Obstet, Leuven, Belgium

[5] Univ Oklahoma, Sarah Cannon Res Inst, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[6] Tennessee Oncol Breast & Gynecol Canc Res, Sarah Cannon Res Inst, Nashville, TN USA

[7] Massachusetts Gen Hosp, Gynecol Oncol Program, Boston, MA USA

[8] Columbia Univ, Med Ctr, Div Gynecol Oncol, New York, NY USA

[9] Grand Hop Charleroi, Serv Oncol Hematol, Charleroi, Belgium

[10] Regeneron Pharmaceut Inc, Biostat, Tarrytown, NY USA

[11] Regeneron Pharmaceut Inc, Global Patient Safety, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Precis Med, Tarrytown, NY USA

[13] Regeneron Pharmaceut Inc, Oncol Clin Dev, Tarrytown, NY USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Weill Cornell Med Coll, Gynecol Med Oncol Serv, New York, NY USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO011LBA

引用

页码：A9 / A10

页数：2

共 50 条

[41] Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients
Barlow, P.
Jameson, M.
Lin, C.
Wu, J.
Pirzkall, A.
Lee, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S721 - S721
[42] Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
Gong, Jifang
Liu, Chang
Yao, Jun
Xue, Junli
Dai, Jing
Ji, Yinghua
Markman, Ben
Hiong, Alison
Yang, Xiuli
Zhao, Rusen
Zheng, Yi
Li, Qingshan
Wu, Jun
Barve, Minal A.
Ariyapperuma, Mihitha Hashara
Richardson, Gary Edward
Qin, Xia
Qin, Crystal Ying
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer
Jiang, Wei
Ouyang, Xueyan
Li, Chunyan
Long, Yixiu
Chen, Wei
Ji, Zhaodong
Shen, Xuxia
Xiang, Libing
Yang, Huijuan
IMMUNOLOGY, 2023, 170 (03) : 419 - 438
[44] TARGETING PI3K INCREASES THE EFFICACY OF ANTI-PD-1 ANTIBODY IN CERVICAL CANCER
Jiang, Wei
Yang, Huijuan
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A56 - A56
[45] NB202: A bispecific anti-PD1/TIM-3 antibody for cancer immunotherapy
Dong, Jinyu
Zhang, Yu
Wang, Binbin
Wang, Dong
Bu, Tingting
Ni, Jie
Nayak, Bishnu
Dong, Xin
CANCER RESEARCH, 2024, 84 (06)
[46] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Trial-inprogress update.
Segal, Neil Howard
Pelster, Meredith
Girda, Eugenia
Fong, Lawrence
Olszanski, Anthony J.
Han, Hyunsil
Casey, Kerry A.
Li, Siyu
Welf, Erik
Chen, Chieh-I
Skokos, Dimitris
Seebach, Frank A.
Lowy, Israel
Fury, Matthew G.
Mathias, Melissa Divya
Lakhani, Nehal J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS277 - TPS277
[47] Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)
Powderly, John
Spira, Alexander
Kondo, Shunsuke
Doi, Toshihiko
Luke, Jason J.
Rasco, Drew
Gao, Bo
Tanner, Minna
Cassier, Philippe A.
Gazzah, Anas
Italiano, Antoine
Tosi, Diego
Afar, Daniel E.
Parikh, Apurvasena
Engelhardt, Benjamin
Englert, Stefan
Lambert, Stacie L.
Kasichayanula, Sreeneeranj
Mensing, Sven
Menon, Rajeev
Vosganian, Gregory
Tolcher, Anthony
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (01): : 277 - 287
[48] Evaluation of a TNFR2 antibody with and without anti-PD-1 therapy in two murine colon cancer models
Case, Katie
Tran, Lisa
Zheng, Hui
Yang, Michael
Faustman, Denise
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[49] Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
Hamid, Omid
Wang, Ding
Kim, Tae Min
Kim, Sang-We
Lakhani, Nehal J.
Johnson, Melissa Lynne
Groisberg, Roman
Papadopoulos, Kyriakos P.
Kaczmar, John M.
Middleton, Mark R.
Spira, Alexander I.
Williamson, Stephen K.
Rabinowits, Guilherme
Gutierrez, Rodolfo
McKean, Meredith
Chen, Shuquan
Cassidy, James
Mani, Jayakumar
Sims, Tasha Nicholle
Kroog, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
Voskoboynik, Mark
Richardson, Gary Edward
Mileshkin, Linda R.
McNeil, Catriona M.
Horvath, Lisa
Benedetti, Fabio M.
Choy, Gavin S.
Sankar, Neil
McCurry, Shelly
Zhang, Xiaoling
Gao, Min
Shah, Ajit K.
Millward, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →